News and Announcements
Private Mortgages Australia announces a quarterly result of 3.48% (13.95% annualised) for the PMAC Trust – currently offering investors a ‘no application fee’ special
- Published November 01, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Private Mortgages Australia, a boutique Mortgage Manager specialising in sourcing and managing short-term commercial loans secured by real estate mortgages, has announced a quarterly result of 3.48% (13.95% annualised) for the PMAC Trust. The PMAC Trust is a pooled mortgage fund that offers individual investors the benefit of diversification of mortgage transactions.
The Trust has delivered the following return to investors in the past three years:
– FY 2016: 12.50% Annualised Return
– FY 2017: 14.57% Annualised Return
– FY 2018: 12.21% Annualised Return
The Trust is currently offering investors a ‘no application fee’ special so there has never been a better time to invest in Units in the PMAC Trust.
About Private Mortgages Australia
Direct and Pooled investment opportunities available. Directors of PMA, and their associates Co-Invest in mortgages. PMA was established in 2014. Credit Committee has over 50 years combined experience in private lending, investment & credit analysis. Proven track record of providing regular high returns. Cleaner loans, better results.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
